References
- Almeda-Valdes P, Cuevas-Ramos D, Anguilar-Salinas CA. (2009). Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 8:S18–14
- Angulo P. (2002). Nonalcoholic fatty liver disease. N Engl J Med 346:1221–31
- Baker RG, Hayden MS, Ghosh S. (2011). NF-kB, inflammation and metabolic disease. Cell Metab 13:11–22
- Bell S, Degitz K, Quirling M, et al. (2003). Involvement of NF-kappaB signalling in skin physiology and disease. Cell Signal 15:1–7
- Bhatia LS, Curzen NP, Calder PC, Byrne CD. (2012). Non-alcoholic fatty liver disease: A new and important cardiovascular risk factor?. Eur Heart J 33:1190–200
- Boehncke W, Hardt-Weinelt K, Nilsson H, et al. (2001). Anatagnoistic effects of the Staphylococcal Enterotoxin A mutant, SEA on psoriasis in SCID-hu xenogeneic transplantation model. J Invest Dermatol 116:596–601
- Brunt EM, Tiniakos DG. (2002). Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol 16:691–707
- Cia D, Yuan M, Frantz DF, et al. (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183–90
- De Vry CG, Valdez M, Lazarov M, et al. (2005). Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol 125:473–81
- Folch J, Lees M, Stanley GHS. (1957). A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509
- Gerdes S, Rostami-Yazdi M, Mrowietz U. (2010). Adipokines and psoriasis. Exp Dermatol 20:81–7
- Gisondi P, Targher G, Zoppini G, Girolomoni G. (2009). Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 51:758–64
- Gottlieb AB, Chao C, Dann F. (2008). Psoriasis comorbidities. J Dermatol Treat 19:5–21
- Hamminga EA, Van Der Lely AJ, Neumann HAM, Thio HB. (2006). Chronic inflammation in psoriasis and obesity: Implications for therapy. Med Hypotheses 67:768–73
- Hubscher SG. (2006). Histological assessment of non-alcoholic fatty liver disease. Histopathology 49:450–65
- Li M, Zhong X, He Z, et al. (2012). Effect of erythromycin on cigarette-induced histone deacetylase protein expression and nuclear factor-κB activity in human macrophages in vitro. Int Immunopharmacol 12:643–50
- Marchesini G, Bugianesi E, Forlani G, et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–23
- Matsumoto T, Suziki N, Watanabe H, et al. (2004). Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J Gastroenterol 39:1102–5
- Peterson TK. (2006). In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. Basic Clin Pharmacol Toxicol 99:104–15
- Saraceno R, Ruzzetti M, De Martino MU, et al. (2008). Does metabolic syndrome influence psoriasis? Eur Rev Med Pharmacol Sci 12:339–41
- Tetri LH, Basaranoglu M, Brunt EM, et al. (2008). Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 295:G987–95
- Wenk KS, Arrington KC, Ehrlich A. (2010). Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 25:383–91
- Yeom M, Kim S, Lee B, et al. (2012). Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear. J Dermatol Sci 67:101–10